First in Human, Dose Escalation Study of AN4005

PHASE1RecruitingINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

September 27, 2021

Primary Completion Date

August 31, 2025

Study Completion Date

December 31, 2025

Conditions
Advanced Solid TumorAdvanced Lymphoma
Interventions
DRUG

AN4005-dose level 0

50mg BID

DRUG

AN4005-dose level 1

100mg BID

DRUG

AN4005-dose level 2

200mg BID

DRUG

AN4005-dose level 3

400mg BID

DRUG

AN4005-dose level 4

600mg BID

DRUG

AN4005-food effect

Dose to be determined upon the MTD determination

Trial Locations (7)

10461

RECRUITING

Montefiore Einstein Cancer Center, The Bronx

22031

RECRUITING

Next Virginia, Fairfax

29605

RECRUITING

Prisma Health Institute for Translational Oncology Research, Greenville

100142

RECRUITING

Beijing Cancer Hospital, Beijing

150081

RECRUITING

Harbin Medical University Cancer Hospital, Harbin

430000

RECRUITING

Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan

07601

RECRUITING

Hackensack University Medical Center, Hackensack

All Listed Sponsors
lead

Adlai Nortye Biopharma Co., Ltd.

INDUSTRY